Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
Recruiting · NCT06600802 · Registry updated 2025-12-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer | Castration-resistant Metastatic Prostate Cancer; Treated by 177Lutetium-PSMA-617 (Lu-PSMA) | Recruiting | Not applicable | 2025-12-31 | NCT06600802 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Centre Jean Perrin | 15 |
| GIRCI Auvergne Rhone-Alpes | 6 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Jean Perrin | Clermont-Ferrand | France | 58 |
| Centre Paul STRAUSS | Strasbourg | France | 1 |
| CHU de Grenoble | La Tronche | France | 7 |
| Hospices Civiles de Lyon | Pierre-Bénite | France | 1 |
| Hôpital Privé de la Loire | Saint-Etienne | France | 7 |